"Hyperuricemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
| Descriptor ID |
D033461
|
| MeSH Number(s) |
C23.550.449
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hyperuricemia".
Below are MeSH descriptors whose meaning is more specific than "Hyperuricemia".
This graph shows the total number of publications written about "Hyperuricemia" by people in this website by year, and whether "Hyperuricemia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 2 | 0 | 2 |
| 2005 | 3 | 1 | 4 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 4 | 1 | 5 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperuricemia" by people in Profiles.
-
Core-shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management. J Mater Chem B. 2024 Jan 24; 12(4):1064-1076.
-
Transdermal delivery of allopurinol to acute hyperuricemic mice via polymer microneedles for the regulation of serum uric acid levels. Biomater Sci. 2023 Feb 28; 11(5):1704-1713.
-
Clustering Patients With Gout Based on Comorbidities and Biomarkers: A Cross-Sectional Study. J Rheumatol. 2023 06; 50(6):817-826.
-
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout. RMD Open. 2021 04; 7(2).
-
Genetic correlations between traits associated with hyperuricemia, gout, and comorbidities. Eur J Hum Genet. 2021 09; 29(9):1438-1445.
-
Response to: 'Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills et al. Ann Rheum Dis. 2022 07; 81(7):e125.
-
Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'' by Hsu et al. Ann Rheum Dis. 2022 07; 81(7):e123.
-
Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma et al. Ann Rheum Dis. 2022 06; 81(6):e108.
-
Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol. 2020 Feb; 7(2):e168-e176.
-
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Leuk Res. 2020 02; 89:106298.